Reviewer’s report

Title: Improvement in health-related quality of life in osteoporosis patients treated with teriparatide

Version: 2 Date: 8 April 2008

Reviewer: Stuart Silverman

Reviewer’s report:

A prospective study of HRQOL in patients given teriparatide in open label
No control group
Data from 3, and 6 months are pooled
I have some questions:
1. The authors report reduction in symptoms. Was there any reduction in analgesic use?
2. Any differences between patients with and without prevalent fracture?
3. What was adherence?
4. On page 6 statistically sig differences are reported but are they clinically significant? what is minimal clinically significant change and how was it determined?

Recommend accept with major revision
I am willing to review revision